Overexpression of Apolipoprotein B in the Heart Impedes Cardiac Triglyceride Accumulation and Development of Cardiac Dysfunction in Diabetic Mice*

The heart secretes apolipoprotein B (apoB) containing lipoproteins. Herein, we examined whether the overexpression of a human apoB transgene in the heart affects triglyceride accumulation and development of cardiac dysfunction in streptozotocin-treated diabetic mice. Blood glucose, plasma free fatty acids, and plasma triglycerides were similarly affected in diabetic wild type mice and diabetic apoB transgenic mice as compared with non-diabetic mice of the same genotype. After 12 weeks, heart triglycerides were increased by 48% in diabetic wild type mice. These mice displayed an increased expression of brain natriuretic peptide and deterioration of heart function on echocardiography. In diabetic apoB transgenic mice, heart triglyceride levels were identical to those in non-diabetic wild type and apoB transgenic mice, and brain natriuretic peptide expression as well as echocardiographic indexes of heart function were only marginally affected or unaffected. The findings suggest that triglyceride accumulation in the heart is important for development of diabetic cardiomyopathy in mice, and that lipoprotein formation by cardiomyocytes plays an integrated role in cardiac lipid metabolism.

[1]  L. Nielsen,et al.  Hepatic expression of microsomal triglyceride transfer protein and in vivo secretion of triglyceride-rich lipoproteins are increased in obese diabetic mice. , 2002, Diabetes.

[2]  J. Björkegren,et al.  Lipoprotein Secretion and Triglyceride Stores in the Heart* , 2001, The Journal of Biological Chemistry.

[3]  F. Boomsma,et al.  Plasma A- and B-type natriuretic peptides: physiology, methodology and clinical use. , 2001, Cardiovascular research.

[4]  P. Herrero,et al.  A novel mouse model of lipotoxic cardiomyopathy. , 2001, The Journal of clinical investigation.

[5]  L. Orci,et al.  Diseases of liporegulation: new perspective on obesity and related disorders , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  A. Maseri,et al.  Myocardial Cell Death in Human Diabetes , 2000, Circulation research.

[7]  T. Walther,et al.  Opposite regulation of brain and C-type natriuretic peptides in the streptozotocin-diabetic cardiopathy. , 2000, Journal of molecular endocrinology.

[8]  L. Orci,et al.  Lipotoxic heart disease in obese rats: implications for human obesity. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[9]  P. Douglas,et al.  Abnormal cardiac function in the streptozotocin-induced non-insulin-dependent diabetic rat: noninvasive assessment with doppler echocardiography and contribution of the nitric oxide pathway. , 1999, Journal of the American College of Cardiology.

[10]  B. Hoit,et al.  Noninvasive evaluation of cardiac dysfunction by echocardiography in streptozotocin-induced diabetic rats. , 1999, Journal of cardiac failure.

[11]  R. Davis,et al.  Cell and molecular biology of the assembly and secretion of apolipoprotein B-containing lipoproteins by the liver. , 1999, Biochimica et biophysica acta.

[12]  Kobayashi,et al.  Adenovirus-mediated overexpression of microsomal triglyceride transfer protein (MTP): mechanistic studies on the role of MTP in apolipoprotein B-100 biogenesis, by , 1999, Biochemistry.

[13]  J. Björkegren,et al.  Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice. , 1999, The Journal of clinical investigation.

[14]  S. Young,et al.  The DNA sequences required for apolipoprotein B expression in the heart are distinct from those required for expression in the intestine. , 1999, Journal of molecular and cellular cardiology.

[15]  J. Borén,et al.  Lipoproteins containing apolipoprotein B-100 are secreted by the heart. , 1999, Trends in cardiovascular medicine.

[16]  H. Jamil,et al.  An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. , 1998, Science.

[17]  S. Young,et al.  Knockout of the abetalipoproteinemia gene in mice: reduced lipoprotein secretion in heterozygotes and embryonic lethality in homozygotes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. Borén,et al.  Genes for apolipoprotein B and microsomal triglyceride transfer protein are expressed in the heart: evidence that the heart has the capacity to synthesize and secrete lipoproteins. , 1998, Circulation.

[19]  W. Fiers,et al.  Regulation of microsomal triglyceride transfer protein mRNA expression by endotoxin and cytokines. , 1998, Journal of lipid research.

[20]  L. Nielsen,et al.  Expression of large genomic clones in transgenic mice: new insights into apolipoprotein B structure, function and regulation. , 1998, Current opinion in lipidology.

[21]  J. Borén,et al.  Apo B100-containing lipoproteins are secreted by the heart. , 1998, The Journal of clinical investigation.

[22]  J. Ruiz,et al.  Quantification in the subnanomolar range of phospholipids and neutral lipids by monodimensional thin-layer chromatography and image analysis. , 1997, Journal of lipid research.

[23]  J. Ross,et al.  Transthoracic echocardiography in models of cardiac disease in the mouse. , 1996, Circulation.

[24]  D. L. Wilson,et al.  Increased atherosclerosis in streptozotocin-induced diabetic mice. , 1996, The Journal of clinical investigation.

[25]  Robert V Farese,et al.  Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a). , 1993, The Journal of clinical investigation.

[26]  B. Rodrigues,et al.  Effect of Choline and Methionine Treatment on Cardiac Dysfunction of Diabetic Rats , 1986, Diabetes.

[27]  F. Field,et al.  Microsomal triglyceride transfer protein in CaCo-2 cells: characterization and regulation. , 1997, Journal of lipid research.